Compare Adaptive Biotechnologies Corp (ADPT) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs The Coca-Cola Co K — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.05B), while The Coca-Cola Co K trades at $86.31 (market cap $373.76B). The key difference: The Coca-Cola Co K is far larger — about 92.3× Adaptive Biotechnologies Corp's market cap, and The Coca-Cola Co K pays a 2.44% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | KO | |
|---|---|---|
Market Cap | $4.05B | $373.76B |
Sector | Health | Consumer Staples |
52-Week High | $25.45 | $89.08 |
52-Week Low | $12.30 | $65.67 |
Enterprise Value | $4.12B | $400.93B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Coca-Cola (KO) trades at $86.87, down 0.21% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.97 exceeding the $0.92 forecast. Key valuation ratios include a P/E of 26.09 and ROE of 44.23%, while cash flow trends show robust operational performance. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.
The outlook remains positive with a consensus price target of $95.83, implying 10.3% upside. Strengths include a 64-year dividend growth streak and high profitability, but risks involve regional demand divergence and elevated debt levels. Analyst sentiment is bullish with 60% buy ratings, supporting a favorable investment case for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
